My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.34 -0.01 (-0.07%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights ↗

November 07, 2024

Via Benzinga

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug ↗

October 17, 2024

Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA...

Via Benzinga

Topics Intellectual Property Lawsuit

Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday ↗

October 17, 2024

Via Benzinga

Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts ↗

October 11, 2024

Via Benzinga

FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts ↗

May 14, 2024

Via Benzinga

The Analyst Landscape: 4 Takes On Amicus Therapeutics ↗

December 19, 2023

Via Benzinga

Amicus Therapeutics: Q1 Earnings Insights ↗

May 10, 2023

Via Benzinga

This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today. ↗

May 14, 2024

Via Benzinga

FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗

March 05, 2024

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.

Via Investor's Business Daily

Amicus Therapeutics Stock Sees Improved Relative Strength Rating ↗

February 09, 2024

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.

Via Investor's Business Daily

7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps ↗

November 15, 2023

These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.

Via InvestorPlace

Topics Bankruptcy

The Latest Analyst Ratings for Amicus Therapeutics ↗

March 28, 2023

Via Benzinga

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

Earnings Preview: Amicus Therapeutics ↗

February 28, 2023

Via Benzinga

FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy ↗

October 31, 2022

Via Benzinga

Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗

September 29, 2023

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease ↗

September 28, 2023

The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.

Via Benzinga

Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark ↗

September 28, 2023

Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.

Via Investor's Business Daily

Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade ↗

July 20, 2023

On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81.

Via Investor's Business Daily

Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating ↗

July 17, 2023

On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier.

Via Investor's Business Daily

Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark ↗

May 19, 2023

One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday.

Via Investor's Business Daily

Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics ↗

May 10, 2023

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult

Via Benzinga

'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month ↗

January 25, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec.

Via Benzinga

Recap: Amicus Therapeutics Q3 Earnings ↗

November 07, 2022

Amicus Therapeutics (NASDAQ:FOLD) reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM. Here's what investors need to know about the announcement.

Via Benzinga

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.